Overview

Study of FCN-437c in Patients With Advanced Solid Tumors

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Fochon Pharmaceuticals, Ltd.
Shanghai Fosun Pharmaceutical Development Co, Ltd.